Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

43.48 -0.47 (-1.07%)
Streaming Delayed Price Updated: 2:12 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
From Exelixis
Via Business Wire
Exelixis Inc. (NASDAQ: EXEL) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
News headline image
Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
3 Strong Biotech Performers To Watch As Sector Nears Breakout
As the IBB ETF nears a potential breakout, watch for strong performers like Regeneron Pharmaceuticals, Vertex, and Exelixis to continue outperforming. 
Via MarketBeat
Topics ETFs
News headline image
Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
News headline image
7 Best Cancer Stocks to Invest in Now
The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now. 
Via MarketBeat
Topics Death
News headline image
Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
From Exelixis, Inc.
Via Business Wire
News headline image
Farallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis’ Board
From Farallon Capital Management L.L.C.
Via Business Wire
News headline image
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June
From Exelixis, Inc.
Via Business Wire
News headline image
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside. 
Via MarketBeat
News headline image
Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
News headline image
Farallon Capital Management Comments on Successful Campaign for Change at Exelixis
From Farallon Capital Management L.L.C.
Via Business Wire
News headline image
Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023
From Exelixis, Inc.
Via Business Wire
News headline image
Farallon Capital Urges Exelixis Shareholders to Support Change by Electing Its Three Highly Qualified Director Candidates
From Farallon Capital Management L.L.C.
Via Business Wire
News headline image
Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Advances Board Refreshment Plan
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Reiterates Commitment to Shareholder Value Creation
From Exelixis, Inc.
Via Business Wire
News headline image
Farallon Issues Letter to Exelixis Board of Directors Outlining Case for Change
From Farallon Capital Management L.L.C.
Via Business Wire
News headline image
Exelixis Announces $550 Million Share Repurchase Program
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
From Exelixis, Inc.
Via Business Wire
News headline image
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
From Bristol Myers Squibb and Exelixis, Inc.
Via Business Wire
News headline image
Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors
From Exelixis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.